Palvella Therapeutics (PVLA) Corporate presentation summary

Strategic vision and pipeline

• Aims to become a leading rare disease biopharma with 10+ first-in-disease therapies in late-stage development or launched by 2026 and beyond.

• Focuses on serious, rare skin diseases and vascular malformations, leveraging a pipeline-in-a-product strategy to expand addressable markets.

• QTORIN™ platform enables rapid, capital-efficient development of topical therapies with high drug loading, dermal engagement, and strong IP protection.

• Announced programs include QTORIN™ rapamycin for microcystic lymphatic malformations (mLM), cutaneous venous malformations (cVM), angiokeratomas, and QTORIN™ pitavastatin for DSAP.

• Two new rare disease programs are expected to be added to the pipeline in 2H 2026.

Clinical development and results

• Phase 3 SELVA trial for QTORIN™ rapamycin in mLM achieved highly significant results across all endpoints, with 95% of participants showing improvement and 86% rated as "Much Improved" or better.

• Safety profile was favorable, with no severe or serious treatment-related adverse events and low systemic absorption.

• Phase 2 TOIVA study in cVMs showed 73% of participants improved at 12 weeks, supporting progression to Phase 3.

• QTORIN™ pitavastatin demonstrated promising preclinical attributes for DSAP, with strong dermal penetration and low systemic absorption.

• All clinical programs target diseases with no FDA-approved therapies and high unmet need.

Regulatory and market positioning

• QTORIN™ rapamycin for mLM has Breakthrough Therapy, Fast Track, and Orphan Drug Designations, with NDA submission planned for 2H 2026 and potential approval in 1H 2027.

• Multi-layered exclusivity strategy includes six issued U.S. patents (protection through at least 2038), trade secrets, and regulatory exclusivities.

• Commercial build-out underway for mLM, targeting a multi-billion dollar, uncontested U.S. market with >30k diagnosed patients and strong physician intent to prescribe.

• Pricing strategy supported by orphan analogues, with expected annual pricing of $100k–$200k per patient and peak U.S. sales potential of $1–3 billion.

• Highly concentrated prescriber base enables efficient commercialization with a focused sales force.